Skip to search formSkip to main contentSkip to account menu

TCV 309

Known as: TCV-309 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Platelet Aggregation InhibitorsPyridinium CompoundsTetrahydroisoquinolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Pain‐releasing action of Platelet‐activating factor (PAF) antagonists in neuropathic pain animal models and the mechanisms of action
Platelet‐activating factor (PAF) has been implicated in the pathology of neuropathic pain. Previous studies reported that PAF… 
Highly Cited
2000
Highly Cited
2000
Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II…
Sepsis and organ failure remain the main cause of death on the ICU. Sepsis is characterized by a severe inflammatory response, in… 
1999
1999
Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/reperfusion injury.
1998
1998
Platelet-activating factor receptor antagonist attenuates endotoxin-induced vascular hyporeactivity in the pithed rat.
1998
1998
The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury.
1998
1998
Triple role of platelet-activating factor in eosinophil migration across monolayers of lung epithelial cells: eosinophil chemoattractant and priming agent and epithelial cell activator.
Infiltration of eosinophils into the lung lumen is a hallmark of allergic asthmatic inflammation. To reach the lung lumen… 
1996
1996
TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;
In a prospective randomized, double-blind, placebo-controlled clinical study, the safety and efficacy of the platelet-activating… 
1993
1993
Effect of the platelet‐activating factor antagonist, TCV‐309, and the cyclo‐oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock
1 The present study was conducted in order to examine the effects of the platelet‐activating factor (PAF) antagonist, TCV‐309… 
1993
1993
Effects of a platelet activating factor antagonist on oedema formation following burns.
1993
1993
Role of platelet activating factor in ischaemia-reperfusion injury of isolated rabbit hearts: protective effect of a specific platelet activating factor antagonist, TCV-309.
OBJECTIVES The aims were to confirm that platelet activating factor is released during reperfusion after global ischaemia in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)